NYSE:JNJ

Johnson & Johnson to Address Racial and Social Injustice Through Platform that Aims to Eliminate Health Inequities for People of Color

Johnson & Johnson commits $100 million over the next five years to invest in and promote health equity solutions
Press Release

NEW BRUNSWICK, N.J., November 17, 2020 /3BL Media/ – Johnson & Johnson announced today $100 million in commitments and collaborations over the next five years to invest in and promote health equity solutions for Black people and other communities of color in the United States. Society has been significantly impacted by systemic racism, the COVID-19 pandemic, and the economic decline throughout this year, which have all spotlighted healthcare inequities.

How Johnson & Johnson Is Helping Over 40,000 Employees Exercise Their Ability to Vote in a Pandemic

By Liz Ozaist, Global Content Lab Editor-in-Chief, Johnson & Johnson
Summary: 

In an unprecedented year, you need to think of unprecedented ways to help your workforce feel supported—including on Election Day. The company's Chief Human Resources Officer shares why employees can take paid time off to vote this November.

Article

In an unprecedented year, you need to think of unprecedented ways to help your workforce feel supported—including on Election Day. The company's Chief Human Resources Officer shares why employees can take paid time off to vote this November.

4 Ways Johnson & Johnson Is Cultivating Outside-the-Box Innovations for COVID-19

By Jennifer Rainey Marquez
Summary: 

In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.

Article

In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.

Doing Our Part to Wipe Out Environmental Impact

by Caroline Tillett, Global Head, R&D, Johnson & Johnson Consumer Health
Blog

I love my job. As a scientist, I’m constantly challenging myself and my teams to make a meaningful difference on human health. 

Human health is complex and is interdependent with the health of the planet. This is why we design products with the earth in mind. We look to create products in ways that consider the planet’s health without sacrificing the product’s safety and efficacy.

Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19

Summary: 

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Article

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

The Impact of COVID-19 on a Company: 6 Questions for the Chief Financial Officer of Johnson & Johnson

By Liz Ozaist, Global Content Lab Editor-in-Chief, Johnson & Johnson
Summary: 

When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.

Blog

When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.

The Science & Art of Goal Setting: Announcing Johnson & Johnson's New Climate Goals

by Paulette Frank, Worldwide Vice President, Environmental Health, Safety & Sustainability at Johnson & Johnson
Blog

I am so incredibly proud to have had the privilege to share Johnson & Johnson’s new climate goals during this Climate Week NYC 2020.

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
Press Release

NEW BRUNSWICK, N.J., September 28, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.

The Next Phase of Our COVID-19 Vaccine Development

by Alex Gorsky Chairman of the Board and Chief Executive Officer, Johnson & Johnson
Blog

It’s hard to believe that just six months have passed since our scientists identified Janssen’s lead COVID-19 vaccine candidate. We couldn’t have predicted all the changes that have happened since. Two things, however, have been constant: COVID-19 continues to be a devastating pandemic, and Johnson & Johnson has been working around the clock on a potential solution.

The Road to a Vaccine, Season 2, Ep. 7: Is It Really Safe for Schools to Be Open Right Now?

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

As schools reopen—and sometimes close again—what have we learned about the risks of in-person learning? Lisa Ling speaks to school nurse Robin Cogan and pediatrician Dr. Sam Maldonado to find answers and debunk myths around kids and COVID-19.

Pages

Subscribe to NYSE:JNJ